⚖️ Federal & State Regulatory Digest
In this regulatory edition, Dr. Benjamin Caplan synthesizes 3 major policy and administrative filings. Each update reflects changing administrative standards, agency proposals, and clinical implications across cannabinoid healthcare.
Update #1 • Justice Department
DEA Moves to Schedule Five Tryptamine Hallucinogens
Executive Brief: The DEA proposes placing 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT, including qualifying salts and isomers, into Schedule I. If finalized, the rule would impose federal registration, security, recordkeeping, and criminal controls on research, manufacture, distribution, importation, and possession.
Clinical & Patient Impact: These substances are not established treatments, so the immediate effect on routine patient care is limited. The larger clinical concern is that Schedule I requirements can increase research costs, administrative burdens, and delays in generating reliable evidence about safety, toxicity, and possible therapeutic value.
📌 Dr. Caplan’s Perspective: Sensible safety controls should not make careful research unnecessarily difficult. The public is better served when policy supports rigorous study while responding proportionately to credible evidence of harm.
Official Citation: Federal Register (2026-09-23)
Update #2 • Justice Department
Policy Watch: DEA Places Diphenidine in Schedule I
Executive Brief: The DEA has finalized the placement of diphenidine, including qualifying salts and isomers, in Schedule I under the Controlled Substances Act. Anyone manufacturing, distributing, importing, researching, analyzing, or possessing the substance must now comply with Schedule I restrictions and penalties.
Clinical & Patient Impact: Diphenidine has no established role in routine clinical care, but clinicians should recognize its potential appearance in unregulated dissociative drug products and associated intoxication presentations. Researchers face Schedule I registration, security, recordkeeping, and handling requirements that may increase the difficulty and cost of studying the substance.
📌 Dr. Caplan’s Perspective: This is a targeted public health and treaty compliance action, not a broad change to cannabis or conventional prescribing. Clinicians should focus on recognizing possible dissociative toxicity and discussing unknown-source products without judgment.
Official Citation: Federal Register (2026-09-21)
Update #3 • Justice Department
DEA Temporarily Places Four Synthetic Opioids in Schedule I
Executive Brief: DEA has temporarily placed 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine in Schedule I based on an imminent hazard finding. Manufacture, distribution, importation, research, and possession are now subject to federal Schedule I controls and penalties.
Clinical & Patient Impact: These substances have no routine role in established clinical care, so most patients and prescribers will see no direct change in treatment access. Researchers, laboratories, and institutions handling them must comply with Schedule I registration, security, recordkeeping, and other federal requirements, which may slow safety and pharmacology research.
📌 Dr. Caplan’s Perspective: Rapid control of high-risk synthetic opioids is reasonable when credible evidence points to imminent harm. The policy should still preserve a workable research pathway so clinicians and public health officials can understand toxicity, overdose patterns, and potential treatment needs.
Official Citation: Federal Register (2026-08-27)
Policy Digest FAQ
Does this proposal make these five tryptamines federally illegal now?
No. This is a proposed rule, and the new Schedule I controls would take effect only if the DEA publishes a final rule with an effective date.
What is diphenidine, and is it an approved medicine?
Diphenidine is a synthetic dissociative substance sometimes encountered in unregulated drug markets. It is not an FDA-approved medication.
Does this rule affect prescription opioids or medical cannabis?
No. The order applies to four specifically named synthetic substances and their covered chemical forms, not approved prescription opioids or state-authorized cannabis products.
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
